Found 4775 clinical trials
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney.
- 0 views
- 19 Feb, 2024
- 2 locations
Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)
The work proposed pushes the limits of these challenges by providing evidence, identified by a team-based approach to glucose management in an underserved and understudied population supplementing prior data designed to improve outcomes among high-risk patients with type 2 diabetes (T2D) and related cardio metabolic conditions. The proposed intervention is …
- 0 views
- 19 Feb, 2024
- 1 location
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.
- 0 views
- 19 Feb, 2024
- 1 location
UPENN Case Test Trial 2 (Do Not Make Any Changes)
UPENN Case Test Trial 2 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
- 1 location
UPENN Case Test Trial 4 (Do Not Make Any Changes)
UPENN Case Test Trial 4 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
- 1 location
UPENN Case Test Trial 5 (Do Not Make Any Changes)
UPENN Case Test Trial 5 (Do Not Make Any Changes)
- 0 views
- 12 Jun, 2025
- 1 location
UPENN Case Test Trial 12 (Do Not Make Any Changes)
UPENN Case Test Trial 12 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
UPENN Case Test Trial 13 (Do Not Make Any Changes)
UPENN Case Test Trial 13 (Do Not Make Any Changes)
- 0 views
- 15 May, 2025
- 1 location
Metformin for Abdominal Aortic Aneurysm Growth Inhibition
A multi-centre population-based open-label randomized controlled trial with allocation concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA growth in patients with small AAAs who do not have diabetes.
- 0 views
- 19 Feb, 2024
- 1 location
Microbiota and Bone Fragility:Study of the Relation Between Gut Microbiota and Bone Microarchitecture
Gut microbiota regulate metabolism of their human host. Some diseases are associated with variations in gut microbiota diversity and higher fracture risk. Intestinal bacteria synthesize or influence synthesis of factors modulating bone metabolism. The link between gut microbiota and bone was assessed mainly in experimental animal studies. Clinical data, e.g. …
- 0 views
- 19 Feb, 2024
- 1 location